Literature DB >> 22689671

Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Alberto Alvarez-Larrán1, Agueda Ancochea, Anna Angona, Carme Pedro, Francesc García-Pallarols, Luz Martínez-Avilés, Beatriz Bellosillo, Carlos Besses.   

Abstract

The cut off for hemoglobin or hematocrit that indicates the need for an isotopic red cell mass study was investigated in 179 patients with a presumptive diagnosis of polycythemia vera or essential thrombocythemia. Hematocrit showed better diagnostic accuracy than hemoglobin. Hemoglobin over 18.5 g/dL in males or over 16.5 g/dL in females showed a high specificity indicating that red cell mass study could be avoided in such cases, but it showed low sensitivity leading to 46% false negatives. The best value of hematocrit to indicate a red cell mass study was 0.50 L/L in males (specificity 75%, sensitivity 87.5%) and 0.48 L/L in females (specificity 73%, sensitivity 94%). Lowering the hematocrit threshold to 0.48 L/L in males increased sensitivity up to 95%. A red cell mass study should be performed in patients with suspected diagnosis of essential thrombocythemia or polycythemia vera and with hematocrit between 0.48 L/L and 0.52 L/L.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689671      PMCID: PMC3487444          DOI: 10.3324/haematol.2012.067348

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

1.  An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.

Authors:  Peter L Johansson; Soodabeh Safai-Kutti; Jack Kutti
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

2.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2007-03-22       Impact factor: 22.113

3.  Inapparent polycythemia vera: an unrecognized diagnosis.

Authors:  T Lamy; A Devillers; M Bernard; A Moisan; I Grulois; B Drenou; L Amiot; R Fauchet; P Y Le Prise
Journal:  Am J Med       Date:  1997-01       Impact factor: 4.965

4.  A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Authors:  Francesco Passamonti; Elisa Rumi; Marianna Caramella; Chiara Elena; Luca Arcaini; Emanuela Boveri; Cecilia Del Curto; Daniela Pietra; Laura Vanelli; Paolo Bernasconi; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

Review 5.  Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias.

Authors:  N B Westwood; T C Pearson
Journal:  Leuk Lymphoma       Date:  1996-09

Review 6.  Evaluation of diagnostic criteria in polycythemia vera.

Authors:  T C Pearson
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

7.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Authors:  Claire N Harrison; Peter J Campbell; Georgina Buck; Keith Wheatley; Clare L East; David Bareford; Bridget S Wilkins; Jon D van der Walt; John T Reilly; Andrew P Grigg; Paul Revell; Barrie E Woodcock; Anthony R Green
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

8.  Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology.

Authors:  T C Pearson; D L Guthrie; J Simpson; S Chinn; G Barosi; A Ferrant; S M Lewis; Y Najean
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

9.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

10.  Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients.

Authors:  Francisco Cervantes; Alberto Alvarez-Larrán; Carme Talarn; Marta Gómez; Emilio Montserrat
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

View more
  16 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

3.  Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Authors:  Nabih Maslah; Juliette Soret; Christine Dosquet; Laetitia Vercellino; Célia Belkhodja; Marie-Hélène Schlageter; Bruno Cassinat; Jean-Jacques Kiladjian; Christine Chomienne; Stephane Giraudier
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

4.  JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Authors:  Yoko Edahiro; Soji Morishita; Kochi Takahashi; Yumi Hironaka; Yuriko Yahata; Yoshitaka Sunami; Shuichi Shirane; Miyuki Tsutsui; Masaaki Noguchi; Michiaki Koike; Kiyotoshi Imai; Keita Kirito; Naohiro Noda; Yuji Sekiguchi; Satoshi Tsuneda; Akimichi Ohsaka; Marito Araki; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

5.  Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera.

Authors:  Shrinidhi Nathany; Sindhura Lakshmi Koulmane Laxminarayana; Siddharth Tewari; Sushma Belurkar; Ruchee Khanna; Chethan Manohar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-09       Impact factor: 0.900

Review 6.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

Review 7.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

8.  Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Authors:  Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

9.  Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome.

Authors:  Catherine Jones; Yair Levy; Alex W Tong
Journal:  BMJ Case Rep       Date:  2014-12-01

Review 10.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.